Clinical Trial Update: A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications [Phase 4]

View source ↗

Summary

Phase 4 study evaluating eptinezumab in migraine patients with insufficient response to anti-CGRP medications; the trial status is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• VYEPTI (eptinezumab)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Migraine | Phase 4 | Status: ACTIVE_NOT_RECRUITING